ReviewInternational journal of molecular sciences2021
The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Prediction of immunotherapeutic responses by a classifier model based on inflammation-associated tumor microenvironment signatures in colorectal cancer.Discover oncology · 2026Article
- NPLOC4 Constructs Tumor Immunosuppressive Microenvironment in Pan-cancer and Hepatocellular Carcinoma.Current medicinal chemistry · 2026Article
- Feedforward control with personalized nursing measures on respiratory function and psychological status in patients with advanced lung cancer.Scientific reports · 2025Article
- Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas.World journal of clinical oncology · 2025Review
- Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme.Cancer cell international · 2025Article
- [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Article
- The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.PloS one · 2024Article
- Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.Frontiers in immunology · 2024Review
- Label-Free Ratiometric Homogeneous Electrochemical Strategy Based on Exonuclease III-Aided Signal Amplification for Facile and Rapid Detection of miR-378.International journal of analytical chemistry · 2024Article
- Article
- The cytotoxicity ofOncogene · 2023Article
- Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients.BMC cancer · 2023Article
- Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.Thoracic cancer · 2023Article
- Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.Cancers · 2023Review
- ZDHHC9 promotes colon tumor growth by inhibiting effector T cells.Oncology letters · 2023Article
- Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches.International journal of nanomedicine · 2023Review
- Article
- T lymphocyte cell: A pivotal player in lung cancer.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has various limitations; for instance, it is only suitable for specific patients, the response rate is still low in most cases, etc. Colorectal cancer, lung cancer and pancreatic cancer are known as three major death-causing cancers in most countries. In this review, we discuss immunotherapeutic treatment for these three cancers, and consider the option, prospects and limitations of immunotherapy. The development of immunotherapy should focus on the discovery of biomarkers to screen suitable patients, new targets on tumors, neoadjuvant immunotherapy and the combination of immunotherapy with conventional therapeutic methods. We can expect that immunotherapy potentially will develop as one of the best therapies for patients with advanced cancer or poor responses to traditional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.